Recombinant DNA Advisory Committee

Benitec Biopharma announced last week that it has received a written report confirming a favorable review of a planned phase I/IIa clinical trial for its expressed hepatitis C treatment from the National Institutes of Health’s Recombinant DNA Advisory Committee.

Benitec Biopharma hit two key milestones recently in its effort to advance its expressed RNAi-based hepatitis C treatment TT-034 into the clinic, securing a commitment to sell A$7 million ($6.7 million) of its stock to new and existing shareholders and receiving a favorable revie

Benitec Biopharma said this week that it has submitted an application to the National Institutes of Health’s Recombinant DNA Advisory Committee, or RAC, detailing the protocol for its proposed phase I trial of the expressed RNAi hepatitis C treatment TT-034.